| Historic (2004-11-01 to
2009-06-03) |
| Rank |
Entity Name |
Count |
Score |
Coref./Ref. |
| 1 |
diabetes
|
9968 |
110535.3 |
  |
| 2 |
heart attack
|
4611 |
56552.2 |
  |
| 3 |
FDA
|
4561 |
53754.4 |
  |
| 4 |
Actos
|
3040 |
40376.1 |
  |
| 5 |
GlaxoSmithKline
|
2851 |
39806.7 |
  |
| 6 |
Steven Nissen
|
1940 |
25958.5 |
  |
| 7 |
heart failure
|
1870 |
25302.7 |
  |
| 8 |
New England Journal
|
1620 |
22763.4 |
  |
| 9 |
rosiglitazone
|
1490 |
22014.2 |
  |
| 10 |
Medicine
|
1480 |
19967.8 |
  |
| 11 |
Glaxo
|
1340 |
18443.6 |
  |
| 12 |
Cleveland Clinic
|
1170 |
17122.8 |
  |
| 13 |
GlaxoSmithKline PLC
|
870 |
13502.1 |
  |
| 14 |
Vioxx
|
750 |
11680.9 |
  |
| 15 |
cholesterol
|
810 |
11119.7 |
  |
|
| 365 days (2008-06-03 to
2009-06-03) |
| Rank |
Entity Name |
Count |
Score |
Coref./Ref. |
| 1 |
diabetes
|
1648 |
18769.6 |
  |
| 2 |
heart attack
|
991 |
12468.3 |
  |
| 3 |
FDA
|
971 |
11454.1 |
  |
| 4 |
GlaxoSmithKline
|
761 |
10942.8 |
  |
| 5 |
Cleveland Clinic
|
540 |
7784.5 |
  |
| 6 |
Steven Nissen
|
490 |
7049.7 |
  |
| 7 |
rosiglitazone
|
390 |
6284.6 |
  |
| 8 |
Actos
|
340 |
5192.6 |
  |
| 9 |
Public Citizen
|
240 |
3507.0 |
  |
| 10 |
R-Iowa
|
190 |
3125.6 |
  |
| 11 |
Vytorin
|
190 |
3093.5 |
  |
| 12 |
heart failure
|
210 |
3008.6 |
  |
| 13 |
Charles Grassley
|
180 |
2979.4 |
  |
| 14 |
heart disease
|
160 |
2612.5 |
  |
| 15 |
New England Journal
|
160 |
2400.3 |
  |
|
| 30 days (2009-05-04 to
2009-06-03) |
| Rank |
Entity Name |
Count |
Score |
Coref./Ref. |
| 1 |
diabetes
|
60 |
939.4 |
  |
| 2 |
Food and Drug Administration
|
30 |
538.0 |
  |
| 3 |
heart attack
|
30 |
538.0 |
  |
| 4 |
British
|
30 |
510.5 |
  |
| 5 |
FDA
|
30 |
505.1 |
  |
| 6 |
GlaxoSmithKline
|
20 |
328.6 |
  |
| 7 |
SNY
|
10 |
163.2 |
  |
| 8 |
Plavix
|
10 |
161.0 |
  |
| 9 |
Sanofi Aventis
|
10 |
161.0 |
  |
| 10 |
Merck
|
10 |
159.2 |
  |
| 11 |
|
0 |
0 |
  |
| 12 |
|
0 |
0 |
  |
| 13 |
|
0 |
0 |
  |
| 14 |
|
0 |
0 |
  |
| 15 |
|
0 |
0 |
  |
|